Wu Yifang Appointed Chairman of Everest Medicines and Executive Operating Partner at CBC Group

On October 10, Everest Medicines announced the appointment of Wu Yifang as Chairman of the Board of Directors. Mr. Wu was also appointed as Chairman of the Nomination Committee and as a member of the Remuneration Committee. On October 9, Qiaobo Capital, a major shareholder of Everest Medicines, announced the appointment of Wu Yifang as Executive Operating Partner.

Wu Yifang. Image source: Qiao Capital

Everest Medicines also announced that Mr. Fu Wei has been reassigned as a Non-Executive Director of the Company and will no longer serve as Chairman of the Board. In recognition of Mr. Fu’s outstanding contributions and dedication during his tenure as Executive Director and Chairman of the Board, the Board has appointed him as Honorary Chairman to continue providing strategic guidance and decision-making support for the Company’s strategic planning and business development. Mr. Fu also serves as Chief Executive Officer of Qiao Capital. Additionally, Mr. Feng Honggang has resigned as Non-Executive Director of the Company.

According to reports, Wu Yifang boasts over thirty years of extensive professional experience in the pharmaceutical industry. Prior to joining Everest Medicines, he served as Executive President of Fosun International and held the positions of Chairman and Chief Executive Officer of Fosun Pharmaceutical for nearly a decade. During his tenure, as a core member of the management team, he spearheaded Fosun Pharmaceutical’s transformation into a globally leading biopharmaceutical enterprise and successfully introduced BioNTech’s mRNA technology to Greater China. Additionally, Mr. Wu co-founded Wanbang Biopharmaceuticals, serving as its Chairman and CEO, where he laid a solid foundation for the company in the field of biomedical innovation. Mr. Wu obtained an Executive Master of Business Administration (EMBA) degree from Saint Joseph’s University in the United States in 2005.

Kangqiao Capital is an asset management firm based in Asia that focuses on investments in the healthcare and medical industry. Established in 2014, it is committed to creating sustained value by integrating global innovative technologies and talent, and building an ecosystem in the healthcare sector. Currently, its total assets under management amount to $10.5 billion, with its product offerings primarily including buyout funds, fixed-income credit funds, and life sciences infrastructure funds.